FHD-286 in Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma Clinical Trial

Official title:

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects With Metastatic Uveal Melanoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04879017
• Other study ID #: FHD-286-C-001
• Status: Terminated
• Phase: Phase 1
• Start date: May 11, 2021
• Est. completion date: November 30, 2023

Study information

• Verified date: April 2024
• Source: Foghorn Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Description:

This study is an ascending multiple dose clinical trial with expansion arms. It is primarily intended to evaluate the safety and tolerability of FHD-286 when administered orally to subjects with metastatic UM. The Dose Escalation Phase will allow for the determination of the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) in subjects with metastatic UM. This study will also evaluate the PK/PD profiles of multiple dose administration of FHD-286. The Dose Expansion Phase will allow a more robust evaluation of the safety profile of FHD-286, including less frequent toxicities and an assessment of antitumor activity. The data from this study in subjects with metastatic UM, including safety, tolerability, PK/PD findings, and antitumor activity, will form the basis for subsequent clinical development of FHD-286.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 76
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Male or female subjects = 18 years of age
• Subject must have a diagnosis of metastatic histologically or cytologically confirmed UM. If histologic or cytologic confirmation of the primary tumor is not available, clinical confirmation of a diagnosis of metastatic UM, as per standard practice for UM, by the treating investigator can be obtained, and fall into any of the following

categories:

1. Newly diagnosed subject who has not yet received liver-directed or systemic treatment

2. Subjects ineligible for any available therapy likely to convey clinical benefit

3. Subjects who have disease progression after treatment with available therapies and/or who is intolerant to those treatments.

• Subject must have measurable disease by RECIST v1.1, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as = 10 mm with calipers and/or CT scan. Measurable lesions cannot have undergone any local treatment (including liver-directed radio- or immune-therapies) or radiation, unless there has been interim progression of that lesion, nor can any local treatment or radiation involving measurable lesions be anticipated. Note: A malignant lymph node must be = 15 mm on the short axis when assessed by CT scan to be considered pathologically enlarged and measurable.
• Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk in the opinion of the treating physician
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of = 2. a.) Arm 2 (Dose Expansion Phase): Subjects enrolling in Arm 2 must have an ECOG PS of = 3.

Key Exclusion Criteria:

• Subjects who have other malignancy which may interfere with the diagnosis and/or treatment of metastatic UM.
• Subject has thrombocytopenia (platelets < 50 × 109/L) or another major bleeding disorder/diathesis. Note: Subjects with platelets < 50 × 109/L may be permitted to enroll only in Arm 2 of the Dose Expansion Phase at the discretion of the Investigator and the Sponsor.
• Subject has active brain metastases and/or leptomeningeal disease. Subjects with known CNS metastases are only permitted under the following conditions; exceptions may be made on a case-by-case basis with the approval of the Sponsor: Brain metastases must have been stable for approximately 2 months since completion of most recent CNS-directed intervention. Subject may be on corticosteroids so long as the dose is stable for approximately 14 days or decreasing at the time of study entry. Anti-epileptic therapy is allowed so long as medications are not otherwise excluded and seizures have been controlled for approximately 4 weeks since last anti-epileptic medication adjustment.

1. Dose Escalation Phase: Subjects with known CNS metastases that meet the above conditions are permitted to enroll in dose escalation.

2. Arm 1 (Dose Expansion Phase): Subjects with known or suspected CNS metastases are excluded from Arm 1.

3. Arm 2 (Dose Expansion Phase): Subjects with CNS metastases that meet the above conditions are permitted to enroll in Arm 2.

• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections; subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted. Subject has known positive HIV antibody results or acquired immunodeficiency syndrome (AIDS)-related illness; subjects with CD4+ T-cell counts greater than or equal to 350 cells/µL will be permitted, as will subjects who have not had an AIDS-related illness within the past 12 months
• Subjects with an active infection cannot be enrolled until any required antibiotic and/or antifungal therapy has been completed and/or infection is determined to be controlled
• Subjects who have an uncontrolled intercurrent illness.
• Known and possible risk for QT prolongation.
• Subject is on medications that are strong CYP3A inhibitors, are strong CYP3A inducers, or are sensitive CYP3A substrates with narrow TIs
• Subject is on medications with narrow TIs that are sensitive P-gp or BCRP substrates and are administered orally such as digoxin
• Subjects who require clinically significant or increasing doses of systemic steroid therapy or any other systemic immunosuppressive medication. The use of a stable dose of systemic steroids and/or immunosuppressive medication is permitted with Sponsor approval. Local or targeted steroid and immunosuppressive therapies (e.g. inhaled or topical steroids) are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior systemic anticancer therapy is permitted. See exclusion criterion 3 for exceptions regarding steroid therapy for subjects with CNS metastases. See exclusion criterion 13 for exclusions regarding medications that are strong CYP3A inhibitors, strong CYP3A inducers, or sensitive CYP3A substrates with narrow TIs.
• Subjects have undergone any prior treatment with a BRG1/BRM inhibitor.

Related Conditions & MeSH terms

• Melanoma
• Metastatic Uveal Melanoma
• Uveal Neoplasms

Intervention

Drug:
• FHD-286
FHD-286 as a single agent

Locations

Country	Name	City	State
France	Institute Curie Hospital	Paris
Netherlands	Leiden University Medical Center	Leiden
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	MD Anderson Cancer Center	Houston	Texas
United States	The Angeles Clinic and Research Institute	Los Angeles	California
United States	University of Miami Health System, Sylvester Comprehensive Cancer Center	Miami	Florida
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Columbia University, Herbert Irving Comprehensive Cancer Center	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Sidney Kimmel Cancer Center - Jefferson Health	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Foghorn Therapeutics Inc.

Countries where clinical trial is conducted

United States,  France,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of treatment-emergent adverse events (TEAEs)	Dose escalation and expansion	Up to 31 months
Primary	Incidence of adverse events (AEs), serious adverse events (SAEs) including changes in safety laboratory parameters and AEs leading to discontinuation	Dose escalation and expansion	Up to 31 months
Primary	Incidence of dose limiting toxicities (DLTs) during cycle 1 (28 days)	Dose escalation	Cycle 1 (cycle length = 28 days)
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of subjects with evidence of a complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.	Up to 30 months
Secondary	Duration of Response (DOR)	DOR is defined as the time from first documented evidence of CR or PR until the earliest date of documented radiological progression per RECIST 1.1. or death due to any cause among subjects who achieved a CR or PR	Up to 30 months
Secondary	Time to Response (TTR)	TTR is defined as the period of time from the date of first study drug administration until the first objective documentation of a CR or PR per RECIST 1.1.	Up to 30 months
Secondary	Time to Progression (TTP)	TTP is defined as the time from the date of first study drug administration until the start of disease progression per RECIST Version 1.1.	Up to 30 months
Secondary	Progression Free Survival (PFS)	PFS defined as the time from first dose of study treatment until the first date of either objective disease progression per RECIST 1.1. or death due to any cause	Up to 54 months
Secondary	Overall Survival (OS)	OS is defined as the time from first dose of study treatment to the date of death, irrespective of the cause of death	Up to 54 months
Secondary	PK parameter: Area under the plasma concentration time curve (AUC)	Characterization of the PK profile of FHD-286	Cycle 1 (28 days)
Secondary	Plasma concentration vs. time profiles	Plasma concentration of FHD-286 at the scheduled timepoints	Cycle 1 (28 days)